Protara Therapeutics, Inc.
TARA
$3.11
$0.010.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.57% | 6.70% | -13.82% | -17.93% | 14.26% |
| Total Depreciation and Amortization | 18.07% | 1.22% | -2.38% | 1.20% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.55% | 5.20% | 3.51% | -34.66% | -6.91% |
| Change in Net Operating Assets | 147.43% | -252.79% | 35.08% | 323.62% | 156.55% |
| Cash from Operations | 16.74% | -58.07% | -10.36% | -9.72% | 25.94% |
| Capital Expenditure | 50.00% | -- | 100.00% | 85.45% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.19% | -359.16% | 176.58% | -1,079.40% | -87.01% |
| Cash from Investing | 18.22% | -359.35% | 176.56% | -1,097.96% | -87.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.68% | -97.57% | 130.90% | 33,231.85% | -- |
| Repurchase of Common Stock | 100.00% | -- | -- | 100.00% | 90.79% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 89.85% | 86.55% | -207.23% | -- |
| Cash from Financing | -99.54% | -98.23% | -- | -100.00% | 55,484.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 15.94% | -164.24% | 393.57% | -201.27% | 195.37% |